From: Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis
Author | Year | Study region | Recruitment time | Cancer type | Age (%) | No. (high/low) | Outcome | Detection method | Cut-off value | Source of HR | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|
Li et al. | 2016 | China | 2006–2011 | Colorectal cancer | ≥ 65 (52.3%) | 107 (54/53) | OS | qRT-PCR | NA | Data in paper | 7 |
Li et al. | 2017 | China | 2007–2011 | Hepatocellular carcinoma | > 65 (25.0%) | 96 (50/46) | OS | qRT-PCR | Median | Survival curves | 8 |
Wang et al. | 2018 | China | 2016–2017 | Osteosarcoma | ≥ 18 (88.2%) | 32 (18/14) | OS | qRT-PCR | Median | Survival curves | 8 |
Zhang1 et al. | 2016 | China | 2006–2009 | Hepatocellular carcinoma | > 55 (41.7%) | 144 (98/46) | OS DFS | ISH | NA | Data in paper | 6 |
Cui et al. | 2018 | China | 2012–2014 | Gastric cancer | > 55 (50.0%) | 56 (28/28) | OS DFS | qRT-PCR | NA | Survival curves | 6 |
Chen et al. | 2017 | China | 2013–2015 | Lung cancer | > 65 (52.4%) | 42 (21/21) | OS PFS | qRT-PCR | Median | Survival curves | 7 |
Guo et al. | 2018 | China | NA | Cervical cancer | ≥ 45 (47.3%) | 93 (47/46) | OS | qRT-PCR | NA | Survival curves | 7 |
Zhang et al. | 2018 | China | NA | Esophageal carcinoma | ≥ 60 (67.5%) | 80 (37/43) | OS | qRT-PCR | Median | Survival curves | 6 |
Gao et al. | 2018 | China | 2008–2013 | Oral carcinoma | > 60 (45.0%) | 40 (20/20) | OS | qRT-PCR | NA | Data in paper | 8 |
Gao et al. | 2019 | China | NA | Glioma | ≥ 60 (30.8%) | 78 (33/45) | OS | qRT-PCR | Mean | Survival curves | 8 |
Sun et al. | 2018 | China | 2011–2013 | Nasopharyngeal carcinoma | > 50 (52.7%) | 55 (28/27) | OS | qRT-PCR | Median | Survival curves | 6 |
Wang et al. | 2019 | China | NA | Epithelial ovarian cancer | > 55 (43.3%) | 60 (38/22) | OS | qRT-PCR | NA | Survival curves | 6 |
Zhang2 et al. | 2018 | China | NA | Osteosarcoma | > 18 (61.4%) | 140 (70/70) | OS | qRT-PCR | NA | Data in paper | 7 |
Li1 et al. | 2019 | China | NA | Laryngeal carcinoma | ≥ 60 (58.9%) | 56 (28/28) | OS | qRT-PCR | NA | Survival curves | 8 |
Li2 et al. | 2019 | China | 2011–2017 | Glioma | ≥ 50 (52.8%) | 108 (54/54) | OS RFS | qRT-PCR | Median | Data in paper | 6 |